SOPHiA GENETICS (NASDAQ:SOPH) Earns Buy Rating from BTIG Research

Key Points

• BTIG Research reissued a Buy rating with an $8 price target, implying a potential upside of about 57.8%, while analyst coverage is mixed and the MarketBeat consensus remains a "Hold" with a $7.50 target.
• SOPHiA GENETICS reported Q1 EPS of ($0.27), missing estimates of ($0.23) but beating revenue expectations at $21.69M versus $20.40M; the company remains unprofitable with negative margins and return on equity.
• CEO Jurgi Camblong sold 43,129 shares under a Rule 10b5-1 plan to cover tax obligations and insiders have sold ~193,859 shares in the last three months, even as UBS Asset Management significantly increased its stake to 7.63M shares and hedge funds own about 31.6% of the stock.

SOPHiA GENETICS (NASDAQ:SOPH - Get Free Report)'s stock had its "buy" rating reissued by BTIG Research in a research report issued on Wednesday,Benzinga reports. They currently have a $8.00 price target on the stock. BTIG Research's target price would indicate a potential upside of 57.79% from the stock's previous close.

A number of other research analysts have also weighed in on the company. Weiss Ratings reaffirmed a "sell (d-)" rating on shares of SOPHiA GENETICS in a report on Tuesday, April 21st. Guggenheim upped their price objective on SOPHiA GENETICS from $6.00 to $7.00 and gave the stock a "buy" rating in a report on Monday, January 26th. Two analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the stock. According to MarketBeat, SOPHiA GENETICS presently has an average rating of "Hold" and a consensus price target of $7.50.

SOPHiA GENETICS Stock Down 4.2%

SOPH opened at $5.07 on Wednesday. The company has a debt-to-equity ratio of 1.01, a current ratio of 1.96 and a quick ratio of 1.84. The business has a 50 day simple moving average of $4.82 and a 200-day simple moving average of $4.78. The stock has a market capitalization of $347.24 million, a P/E ratio of -9.94 and a beta of 1.01. SOPHiA GENETICS has a 12 month low of $2.59 and a 12 month high of $5.70.

SOPHiA GENETICS (NASDAQ:SOPH - Get Free Report) last announced its quarterly earnings data on Tuesday, May 5th. The company reported ($0.27) earnings per share for the quarter, missing analysts' consensus estimates of ($0.23) by ($0.04). SOPHiA GENETICS had a negative return on equity of 50.60% and a negative net margin of 44.22%.The business had revenue of $21.69 million for the quarter, compared to analyst estimates of $20.40 million.

Insider Buying and Selling at SOPHiA GENETICS

In other news, CEO Jurgi Camblong sold 43,129 shares of the firm's stock in a transaction that occurred on Tuesday, April 14th. The shares were sold at an average price of $4.96, for a total transaction of $213,919.84. Following the completion of the transaction, the chief executive officer directly owned 3,664,440 shares of the company's stock, valued at $18,175,622.40. This trade represents a 1.16% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Over the last three months, insiders have sold 193,859 shares of company stock worth $943,777. Company insiders own 4.88% of the company's stock.

Institutional Inflows and Outflows

A number of hedge funds have recently modified their holdings of SOPH. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC increased its stake in shares of SOPHiA GENETICS by 246.9% during the 1st quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 7,632,871 shares of the company's stock worth $25,341,000 after purchasing an additional 5,432,871 shares in the last quarter. Federated Hermes Inc. increased its stake in shares of SOPHiA GENETICS by 16.4% during the 2nd quarter. Federated Hermes Inc. now owns 220,000 shares of the company's stock worth $682,000 after purchasing an additional 31,000 shares in the last quarter. Akre Capital Management LLC increased its stake in shares of SOPHiA GENETICS by 66.2% during the 2nd quarter. Akre Capital Management LLC now owns 3,719,140 shares of the company's stock worth $11,529,000 after purchasing an additional 1,481,636 shares in the last quarter. Alta Wealth Advisors LLC purchased a new position in shares of SOPHiA GENETICS during the 3rd quarter worth approximately $6,708,000. Finally, Savvy Advisors Inc. purchased a new position in shares of SOPHiA GENETICS during the 3rd quarter worth approximately $48,000. 31.59% of the stock is owned by hedge funds and other institutional investors.

SOPHiA GENETICS Company Profile

SOPHiA GENETICS SA is a data-driven medicine company founded in 2011 and headquartered in La Tène, Switzerland. The firm develops and operates a cloud-native software platform designed to standardize and analyze complex genomic and radiomic data. Its core offering, the SOPHiA DDM™ platform, leverages artificial intelligence and machine learning algorithms to help healthcare institutions, laboratories and biopharmaceutical partners derive actionable insights from next-generation sequencing and medical imaging datasets.

The SOPHiA DDM™ platform supports a range of clinical applications, including oncology, hereditary diseases and rare genetic disorders.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.